Compare Hormel Foods Corp (HRL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Medpace Holdings Inc — how do they compare? Hormel Foods Corp trades at $19.24 (market cap $10.69B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Hormel Foods Corp pays a 6.02% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Medpace Holdings Inc for 14 Days on average.
| HRL | MEDP | |
|---|---|---|
Market Cap | $10.69B | $16.82B |
Volume | 10,041,387 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $630.19 |
52-Week Low | $19.42 | $393.42 |
Typical Hold Time | 99 Days | 14 Days |
Enterprise Value | $12.67B | $16.44B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.19, down 1.84% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 31.32 above industry norms but attractive P/S of 0.88, while profitability metrics remain modest with 2.82% net margin. Recent $1.06B Brakebush acquisition aims to expand foodservice chicken presence, though dividend sustainability concerns emerge as payout ratios rise amid shrinking profit margins.
Outlook remains cautious with analyst consensus at $24.25 offering 26% upside potential, though only 20% recommend Buy. Key risks include margin compression, acquisition integration challenges, and declining organic growth. The 60-year dividend streak provides support, but investors should monitor whether earnings can sustainably cover growing payouts amid inflationary pressures.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
